Samsara BioCapital LLC Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Samsara BioCapital LLC lowered its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 25.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 147,319 shares of the company’s stock after selling 49,106 shares during the period. Day One Biopharmaceuticals comprises about 0.4% of Samsara BioCapital LLC’s portfolio, making the stock its 29th largest holding. Samsara BioCapital LLC owned 0.15% of Day One Biopharmaceuticals worth $2,052,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of DAWN. Parkman Healthcare Partners LLC raised its position in Day One Biopharmaceuticals by 1.7% during the third quarter. Parkman Healthcare Partners LLC now owns 924,140 shares of the company’s stock valued at $12,873,000 after acquiring an additional 15,318 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Day One Biopharmaceuticals by 18.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock valued at $30,307,000 after purchasing an additional 337,928 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $725,000. Maverick Capital Ltd. boosted its holdings in Day One Biopharmaceuticals by 74.5% during the third quarter. Maverick Capital Ltd. now owns 2,114,006 shares of the company’s stock worth $29,448,000 after buying an additional 902,868 shares in the last quarter. Finally, Braidwell LP grew its position in Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after buying an additional 1,837,949 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 1.5 %

NASDAQ:DAWN opened at $13.80 on Thursday. The company’s 50-day moving average is $14.30 and its two-hundred day moving average is $14.10. Day One Biopharmaceuticals, Inc. has a 1-year low of $11.51 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the previous year, the firm posted ($0.54) EPS. Equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Buy” and an average price target of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the sale, the insider now directly owns 1,057,535 shares in the company, valued at $17,026,313.50. This trade represents a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 51,745 shares of company stock worth $775,867 over the last quarter. 8.40% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.